There is no single best treatment for prostate cancer. The right approach depends almost entirely on how advanced the cancer is at diagnosis, how aggressive it appears under a microscope, and your age and overall health. The good news: prostate cancer caught early has a 5-year survival rate of 100%, and even cancer that has spread to nearby lymph nodes shares that same figure. Multiple treatments achieve excellent long-term results for localized disease, so the real decision often comes down to which side effects you’re most willing to accept.
When No Treatment Is the Best Treatment
For low-risk, slow-growing prostate cancer, the most recommended first step is often active surveillance, meaning you skip immediate treatment and instead monitor the cancer closely over time. This isn’t ignoring the problem. It’s a structured program: a confirmatory biopsy within 6 to 24 months of diagnosis, PSA blood tests every three to six months, a rectal exam once a year, an MRI every two to three years, and repeat biopsies every one to five years depending on results. You’ll see your provider at least once a year to map out which tests are coming next.
The logic is straightforward. Many low-grade prostate cancers grow so slowly they’ll never cause symptoms or shorten your life. Treating them immediately means taking on the side effects of surgery or radiation for a cancer that may never have needed it. If monitoring shows the cancer is becoming more aggressive, you move to treatment while it’s still curable.
Surgery vs. Radiation for Localized Cancer
When treatment is warranted for cancer still confined to the prostate, the two primary options are surgical removal (prostatectomy) and radiation therapy. In terms of survival, the two are remarkably similar. One major study found that 10-year survival exceeded 99% for men with lower-risk disease regardless of whether they chose surgery or radiation. Even among men with higher-risk prostate cancer, survival was about 96% for both.
The difference lies in side effects, and those differences are real.
Surgery causes more urinary leakage. Among men with low-risk cancer, 14% who had surgery reported trouble with leaking urine 10 years after treatment, compared with 4% who had radiation. For high-risk cancer, about 25% of surgical patients reported leakage at the 10-year mark versus 11% of radiation patients. Most prostatectomies today are done robotically, which allows for smaller incisions and faster physical recovery, but the nerve-sparing challenges remain the same.
Sexual function takes a hit with both treatments, though the timeline differs. Men who had surgery for low-risk cancer were more likely to report sexual problems in the first five years compared to those who had radiation or chose surveillance. By the 10-year mark, though, those differences had disappeared. For high-risk cancer treated with radiation plus hormone therapy, no difference in sexual function was seen at any time point compared to surgery. Most men with normal sexual function before surgery can eventually regain erections, but it’s a gradual process that can take up to a year.
Neither option is objectively better. If avoiding urinary leakage matters most to you, radiation has an edge. If you prefer to have the cancer physically removed and are comfortable with a longer recovery of bladder and sexual function, surgery may feel like the right call.
Hormone Therapy and Its Role
Hormone therapy, also called androgen deprivation therapy, works by cutting off the testosterone that fuels prostate cancer growth. It’s rarely used alone for localized cancer but plays a central role alongside radiation for higher-risk or locally advanced disease, and it’s the backbone of treatment for cancer that has spread.
The side effects are significant because testosterone affects nearly every system in the body. Common effects include hot flashes, loss of interest in sex, erectile dysfunction, weight gain, fatigue, loss of muscle mass, mood changes, insulin resistance, breast tissue growth, and bone thinning. Long-term use carries a real risk of bone fractures from density loss. Medications that strengthen bones (bisphosphonates or other bone-protecting drugs) can slow or reverse that loss, and regular exercise has been shown to help with bone loss, muscle loss, weight gain, fatigue, and insulin resistance all at once.
Treating Cancer That Has Spread
When prostate cancer metastasizes, the 5-year survival rate drops to about 40%. Treatment at this stage focuses on controlling growth and extending life rather than curing the disease. The standard approach combines hormone therapy with additional agents, and recent years have brought major advances in how these combinations work.
For hormone-sensitive metastatic cancer (cancer that still responds to testosterone suppression), current guidelines recommend “doublet” or “triplet” therapy. This means pairing standard hormone therapy with a next-generation hormone-blocking drug, chemotherapy, or both. These intensified combinations have consistently shown better outcomes than hormone therapy alone.
When cancer stops responding to hormone suppression, it’s classified as castration-resistant. At this stage, treatment becomes more personalized. Genetic testing of the tumor plays a critical role. About 20 to 25% of advanced prostate cancers carry mutations in DNA repair genes, particularly BRCA1 and BRCA2. For these patients, targeted drugs called PARP inhibitors can be highly effective. In clinical trials, men with BRCA mutations treated with a PARP inhibitor saw their cancer held in check nearly twice as long as those on standard therapy. Combinations of PARP inhibitors with next-generation hormone drugs showed even stronger results for BRCA-positive patients.
Radioligand therapy is another option for advanced disease. It works by attaching a radioactive molecule to a compound that seeks out prostate cancer cells, delivering radiation directly to tumors throughout the body. Interestingly, patients with BRCA mutations may not respond as well to this approach, which is one reason genetic testing matters so much for sequencing treatments correctly.
Focal Therapies: HIFU and Cryotherapy
Newer techniques like high-intensity focused ultrasound (HIFU) and cryotherapy (freezing cancer cells) aim to destroy only the tumor within the prostate, leaving the rest of the gland intact. The appeal is obvious: fewer side effects than surgery or whole-gland radiation. Some doctors now offer HIFU as a first treatment for early-stage, low-risk cancers.
The catch is that long-term data is still limited. Most expert groups don’t recommend these focal therapies as a first choice unless surgery and radiation aren’t good options. It’s not yet clear whether they match the long-term effectiveness of the standard treatments. They’re also not ideal if the tumor sits close to the urethra or rectum. One practical advantage: if cancer returns after focal treatment, the procedure can often be repeated, or you can still pursue surgery or radiation afterward. Cryotherapy is more established as a salvage option for cancer that comes back after radiation.
How Treatment Decisions Actually Get Made
In practice, the “best” treatment is determined by a handful of factors working together. Your Gleason score (how abnormal the cancer cells look) and PSA level establish risk category. Imaging shows whether the cancer has spread. Your age matters because a 55-year-old with decades of life ahead may weigh options differently than a 75-year-old with other health conditions. And personal priorities, whether you’re most concerned about sexual function, urinary control, or simply having the cancer out of your body, legitimately shape the decision.
For low-risk cancer: active surveillance is the recommended starting point. For intermediate-risk cancer: surgery or radiation, sometimes with a short course of hormone therapy. For high-risk localized cancer: radiation combined with long-term hormone therapy, or surgery followed by additional treatment if needed. For metastatic cancer: combination hormone therapy, with genetic testing guiding later-line options. Each step along this spectrum has strong evidence behind it, and the treatment landscape has expanded substantially in the past five years, particularly for advanced disease.